| THE UAB RESEARCH FOUNDATION Patent applications |
| Patent application number | Title | Published |
|---|
| 20120122724 | Agents and Methods Related to Reducing Resistance to Apoptosis-Inducing Death Receptor Agonists - Provided herein is a method of reversing or preventing a target cell's resistance to a death receptor agonist. Also provided are methods of screening for biomarkers resistance of and monitoring resistance to death receptor agonists. Also provided are methods of selectively inducing apoptosis in a target cell, treating a subject with cancer, autoimmune or inflammatory diseases, comprising administering compositions provided herein. Further provided are compositions comprising agents that modulate CARD containing proteins. | 05-17-2012 |
| 20120107929 | Variable Lymphocyte Receptors, Related Polypeptides and Nucleic Acids, and Uses Thereof - Disclosed are compositions and methods related to variable lymphocyte receptors (VLRs). | 05-03-2012 |
| 20120076792 | ANTIBODY SELECTIVE FOR A TUMOR NECROSIS FACTOR-RELATED APOPTOSIS-INDUCING LIGAND RECEPTOR AND USES THEREOF - An antibody of the invention interacts with human DR5 to produce agonistic or antagonistic effects downstream of o the receptor including inhibition of cell proliferation and apoptosis. Nucleic acid sequences and amino acid sequences of anti-DR5 antibodies have been elucidated and vectors and cells containing and expressing these sequences have been generated. Methods and uses for the antibodies are detailed including treatment of apoptosis-related disease and treatment of dysregulated cell growth. | 03-29-2012 |
| 20120065247 | MODULATING IRES-MEDIATED TRANSLATION - Provided herein are compounds and methods for use in preventing or treating a viral infection mediated by a virus comprising an IRES-containing RNA molecule or cancer related to an increase or decrease in IRES-mediated translation of an RNA molecule. Also provided are methods of inhibiting or promoting IRES-mediated translation. Also provided are methods of screening for an agent that inhibits IRES-mediated translation. | 03-15-2012 |
| 20120055792 | MSP NANOPORES AND RELATED METHODS - Provided herein are | 03-08-2012 |
| 20120045518 | ENHANCING COAGULATION OR REDUCING FIBRINOLYSIS - Methods for controlling bleeding (e.g., enhancing coagulation and reducing fibrinolysis) in a subject are disclosed. The methods include selecting a subject in need of enhanced coagulation or reduced fibrinolysis, and administering to the subject a carbon monoxide releasing molecule (CORM). Examples of CORMs include tricarbonyldichloro-ruthenium (II) dimer, tricarbonylchloro-(glycinato)ruthenium (II), sodium boranocarbonate, dimanganese decacarbonyl, and iron pentacarbonyl. Further disclosed are compositions and methods for treating a subject in need of a blood product by administering to the subject a composition including a CORM and a blood product (e.g., cryoprecipitate or fresh frozen plasma). | 02-23-2012 |
| 20120035095 | ORALLY ADMINISTERED PEPTIDES SYNERGIZE STATIN ACTIVITY - This invention provides novel peptides that ameliorate one or more symptoms of atherosclerosis. The peptides are highly stable and readily administered via an oral route. The peptides are effective to stimulate the formation and cycling of pre-beta high density lipoprotein-like particles and/or to promote lipid transport and detoxification. This invention also provides a method of tracking a peptide in a mammal. In addition, the peptides inhibit osteoporosis. When administered with a statin, the peptides enhance the activity of the statin permitting the statin to be used at significantly lower dosages and/or cause the statins to be significantly more anti-inflammatory at any given dose. | 02-09-2012 |
| 20110311653 | USE OF NITRITE SALTS IN CHRONIC ISCHEMIA - Methods of treating a subject who has chronic tissue ischemia are disclosed. The methods can include administering to the subject a pharmaceutical composition comprising inorganic nitrite or a pharmaceutically acceptable salt thereof, for a time and in an amount sufficient to result in blood vessel growth in the ischemic tissue. The subject can be diagnosed as having a medical condition that results in persistent or recurring restriction of blood supply to a tissue, for example, peripheral artery disease, diabetes, atherosclerotic cardiovascular disease or defective wound healing. The methods can include the step of identifying a suitable subject. | 12-22-2011 |
| 20110293515 | HETEROFUNCTIONAL SEGMENT-POLY (ETHYLENE GLYCOL) POLYMERS AS DELIVERY VEHICLES - Heterofunctional segment-poly(ethylene glycol) polymers, conjugates of these molecules with therapeutic and/or imaging agents, and methods for their use are disclosed. The heterofunctional segment-poly(ethylene glycol) polymers are useful as drug delivery conjugates, i.e., the heterofunctional segment-poly(ethylene glycol) polymers can be covalently attached to therapeutic agents (e.g., pharmaceutically active agents) and serve as delivery vehicles for the therapeutic agents. The heterofunctional segment-poly(ethylene glycol) polymers are also useful as imaging agent conjugates, i.e. the heterofunctional segment-poly(ethylene glycol) polymers can be covalently attached to imaging agents (e.g., tracers, imaging atoms, and imaging molecules) and serve as delivery vehicles for the imaging agents. Also disclosed are methods for treating a subject by administering to the subject an effective amount of the polymers conjugated to a therapeutic agent, an imaging agent, or a mixture thereof. | 12-01-2011 |
| 20110275635 | SMALL MOLECULE INHIBITORS OF NADS, NAMNAT, AND NMNAT - Small molecule inhibitors of bacterial nicotinamide adenine dinucleotide synthetase (NADs), bacterial nicotinic acid mononucleotide adenylyltransferase (NaMNAT), and human nicotinamide mononucleotide adenylyltransferase (NMNAT) are provided, as well as methods of making and using the inhibitors. | 11-10-2011 |
| 20110268753 | PROCESS FOR REGULATING IMMUNE RESPONSE - The discovery of FcγRIIc expression on B-cells allows several new methods of prediction or regulation of immune responses. A process of altering an immune response in a subject is provided by altering the expression level or activity of FcγRIIc on a cell. The relative ratio of activating FcγRIIc to inhibitory FcγRIIb levels in an immune cell allows prediction of the presence or absence of immune disease or abnormality such as rheumatoid arthritis or systemic lupus erythematosus. Inventive processes are provided whereby the relative levels of activating to inhibitory receptor expression in a subject is compared to an established inventive classification system to predict an immune response to a therapeutic, the presence or absence of disease, or the magnitude, duration, or timing of an immune response in the subject. | 11-03-2011 |
| 20110256557 | IDENTIFYING PARATHYROID HORMONE AGONISTS AND ANTAGONISTS - Provided herein are methods of screening for an agent that is a PTH agonist or antagonist. For example, provided is a method of screening for an agent that is a PTH agonist or antagonist, the method comprising contacting a cell with LRP6 and the agent to be screened, wherein the cell comprises a PTH1R, and determining the level of LRP6 binding to the PTH1R. An increased level of LRP6 binding to the PTH1R compared to a control indicates the agent is a PTH agonist. A decreased level of LRP6 binding to the PTH1R compared to a control indicates the agent is a PTH antagonist. Also provided are methods of treating a skeletal disorder in a subject, wherein the skeletal disorder is characterized by proliferative bone growth or reduced bone density. | 10-20-2011 |
| 20110230813 | Process for Metabolic Control and High Solute Clearance and Solutions for Use Therein - The present disclosure describes novel standardized citrate replacement fluid solutions and a standardized dialysate solution for use with CRRT methods. The standardized citrate replacement fluid solutions and standardized dialysate solutions do not require modification based on the clinical status of the individual patients. The use of the standardized solutions described herein offers significant advantages over the prior art solutions used in CRRT. The present disclosure describes superior metabolic and electrolyte control and significantly increased dialyzer patency in: (a) 24 intensive care unit (ICU) patients with ARF using a 0.67% trisodium citrate replacement fluid solution, and (b) 32 ICU patients with ARF using a 0.5% trisodium citrate replacement fluid solution. Both groups were treated with Bicarbonate-25 dialysate and achieved effluent rates of 35 mL/kg/hr. | 09-22-2011 |
| 20110229964 | Fusion Protein Delivery System and Uses Thereof - The present invention provides a composition of matter, comprising: DNA encoding a viral Vpx protein fused to DNA encoding a protein. In another embodiment of the present invention, there is provided a composition of matter comprising: DNA encoding a viral Vpr protein fused to DNA encoding a protein. The present invention further provides DNA, vectors and methods for expressing a lentiviral pol gene in trans, independent of the lentiviral gag-pol. A gene transduction element is optionally delivered to a lentiviral vector according to the present invention. Also provided are various methods of delivering a virus inhibitory molecule to a target in an animal. Further provided is a pharmaceutical composition. | 09-22-2011 |
| 20110212073 | PURINE NUCLEOSIDE PHOSPHORYLASE AS ENZYMATIC ACTIVATOR OF NUCLEOSIDE PRODRUGS - A process for inhibiting a mammalian cancerous cell or virally infected cell includes providing a | 09-01-2011 |
| 20110189186 | AFFECTING BONE RELATED CONDITIONS USING CD68 BLOCKING AGENTS - Methods of treating, reducing, and/or preventing cancer metastasis to bone using CD68 blocking agents are provided. For example, the methods can be used to reduce breast cancer metastasis to bone. Also provided are methods of treating, reducing, and/or preventing bone resorption in a subject using CD68 blocking agents. For example, the methods can be used to treat osteoporosis. | 08-04-2011 |
| 20110183341 | Use of 14-3-3-Proteins in Treatment and Prevention of Neurodegeneration - The present disclosure is directed to methods for treatment and prevention of disease states characterized by a decreased 14-3-3 polypeptide expression or activity. In one embodiment, the present disclosure provides methods for the treatment and/or prevention of Parkinson's disease, neurodegeneration and/or diseases characterized, at least in part, by neurodegeneration, by increasing a 14-3-3 polypeptide activity. | 07-28-2011 |
| 20110160266 | Novel Anti-Arrhythmia Agent - It has been discovered that SKF-96365 prevents and reverses ectopic activity in myocyte cells, and that SKF-96365 is effective against all types of ectopic activity. Methods are provided using SKF-96365 and its derivatives to prevent and reverse electromechanical disorders of myocytes; these include methods of treatment and prevention of cardiac arrhythmias in human and animal subjects. These further include methods of preventing and reversing arrhythmias in cardiac muscles and hearts. These further include methods of preventing and reversing spontaneous mechanical activity in a myocyte. Pharmaceutical drugs for the treatment and prevention of cardiac arrhythmia are described, based on SKF-96365. Kits for employing the methods are also described. | 06-30-2011 |
| 20110160123 | TARGETING THE EFFLUX SYSTEMS OF MYCOBACTERIUM TUBERCULOSIS - Provided herein are methods of reducing drug resistance in | 06-30-2011 |
| 20110144125 | Anti-Arrhythmia Agents, Methods of Their Use, Methods of Their Identification and Kits Therefore - The disclosure describes an animal model for simulating cardiac arrhythmia. Methods of discovering new anti-arrhythmia drugs using the model are described. Novel anti-arrhythmia agents are provided, as are pharmaceutical compositions made from the agents. Methods of inhibiting spontaneous mechanical activity in myocardially-derived biological systems, and methods of treating and preventing cardiac arrhythmia based on novel anti-arrhythmia agents are described. Kits for performing the above methods are also described. | 06-16-2011 |
| 20110141437 | Method and Apparatus for the Detection of Impaired Dark Adaptation - The present method describes a new method for the measurement of dark adaptation. The dark adaptation status of subjects may then be used to identify those subjects who are at risk of developing and/or who are currently suffering from a variety of disease states having their clinical manifestations in impaired dark adaptation. The disease states include, but are not limited to, age related macular degeneration, vitamin A deficiency, Sorsby's Fundus Dystrophy, late autosomal dominant retinal degeneration, retinal impairment related to diabetes and diabetic retinopathy. An apparatus for administering the test method described is also provided. | 06-16-2011 |
| 20110135678 | TOLERIZING AGENTS - Described herein is the development of fusion proteins useful for inducing tolerance in a subject. In particular embodiments, the tolerizing agents are useful for influence autoimmune, inflammatory, and/or allergic reactions. Example tolerizing fusion proteins contain a targeting portion (which delivers the fusion protein) and a toleragen or allergen or other antigen to which tolerance is desired in a subject. In particular examples, it is demonstrated that a pσ1 fusion protein, when administered orally, facilitates systemic and mucosal tolerance. Also described is the nasal delivery of fusion proteins, for instance for restoring immunogenicity. | 06-09-2011 |
| 20110104168 | DETOXIFIED PNEUMOCOCCAL NEURAMINIDASE AND USES THEREOF - Provided herein are compositions designed to reduce or prevent pneuomococcal infections, nasal carriage, nasal colonization, and central nervous system invasion. Provided herein is a composition comprising a polypeptide comprising the amino acid sequence of SEQ ID NO: 19 or a variant thereof that can elicit an anti-neuraminidase immune response. Further provided are methods of making and using the compositions disclosed herein. Specifically provided are methods of generating antibodies in a subject comprising administering to the subject an agent or composition taught herein. Also provided are methods of reducing or preventing nasal carriage or pneumococcal infection in a subject comprising administering to the subject a composition taught herein. | 05-05-2011 |
| 20110104143 | Treating Basal-Like Genotype Cancers - Provided herein are methods of treating a subject with cancer comprising administering to the subject a death receptor agonist. Also provided herein are methods of screening a breast cancer cell for responsiveness to a DR5 agonist. Further provided herein are antibodies that selectively bind an N-terminal CARD of DDX3, a DDX3 lacking an N-terminal CARD, and an 80 kDa baculovirus TAP repeat (BIR). | 05-05-2011 |
| 20110086047 | FC RECEPTOR HOMOLOG ANTIBODIES AND USES THEREOF - Provided herein are antibodies having the same epitope specificity as an antibody produced by the hybridoma cell line deposited with the American Type Culture Collection as hybridoma 4-2A6, 1-5A3, or 1-3B4. Further provided herein are methods of identifying and selecting cells that express FcRH1 or FcRH4. Methods of diagnosing and treating a subject with a malignancy of a hematopoietic cell lineage or an autoimmune disease and methods of modulating a humoral immune response in a subject are also provided herein. Further provided herein are polypeptides comprising one or more complementary determining regions of the disclosed antibodies and nucleic acids that encode the disclosed polypeptides. | 04-14-2011 |
| 20110076304 | ADAPTER MOLECULE FOR THE DELIVERY OF ADENOVIRUS VECTORS - The invention relates to an adapter protein comprising a coxackievirus and adenovirus receptor (CAR) region and a human CD40 ligand and to the uses thereof for promoting adenoviral transduction of dendritic cells while at the same time promoting maturation of the DCs. The invention also relates to pharmaceutical compositions comprising said adapter protein and an adenovirus encoding an antigen and the uses thereof in a method for eliciting an immune response against the antigen encoded in said adenovirus as well as to antigen-loaded dendritic cells obtained the adaptor protein and an adenovirus and to the uses thereof in a method of eliciting an immune response against the antigen encoded in the adenovirus. | 03-31-2011 |
| 20110064721 | CATHEPSIN-D NEUROPROTECTION - Provided herein are methods and compositions for promoting neuroprotection in a subject and for treating a neural disorder associated with protein aggregation comprising administering to the subject an agent that increases expression or activity of cathepsin-D. Also provided are methods of screening for agents that increase expression or activity of cathepsin-D and methods of screening for neuroprotective agents. | 03-17-2011 |
| 20110054037 | BIS-AROMATIC ANTICANCER AGENTS - Treatment of cancer includes administering a compound of formula (I) to a subject. In particular, treatment of colorectal cancer is described. | 03-03-2011 |
| 20110008324 | Antibody Selective for a Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor and Uses Thereof - An antibody of the invention interacts with human DR5 to produce agonistic or antagonistic effects downstream of the receptor including inhibition of cell proliferation and apoptosis. Nucleic acid sequences and amino acid sequences of anti-DR5 antibodies have been elucidated and vectors and cells containing and expressing these sequences have been generated. Methods and uses for the antibodies are detailed including treatment of apoptosis-related disease and treatment of dysregulated cell growth. | 01-13-2011 |
| 20110007276 | Method and Apparatus for the Detection of Impaired Dark Adaptation - The present method describes a new method for the measurement of dark adaptation. The dark adaptation status of subjects may then be used to identify those subjects who are at risk of developing and/or who are currently suffering from a variety of disease states having their clinical manifestations in impaired dark adaptation. The disease states include, but are not limited to, age related macular degeneration, vitamin A deficiency, Sorsby's Fundus Dystrophy, late autosomal dominant retinal degeneration, retinal impairment related to diabetes and diabetic retinopathy. An apparatus for administering the test method described is also provided. | 01-13-2011 |
| 20110003868 | TREATMENT OF A NEUROPATHY WITH RAPID RELEASE AMINOPYRIDINE - A process for treating neuropathy includes administration to a patient suffering from a neuropathy more than 5 and less than 18 mg of aminopyridine in a dose. The aminopyridine is formulated in an immediate release formulation. At least two such doses are provided per day to create spike serum plasma levels of aminopyridine sufficient to drive the aminopyridine across the blood-nerve barrier. | 01-06-2011 |
| 20110002962 | Immunogenic PcpA Polypeptides and Uses Thereof - Provided herein are compositions and methods for eliciting an immune response against | 01-06-2011 |
| 20110002887 | COMBINATIONS OF ANTIBODIES SELECTIVE FOR DR5 AND OTHER THERAPEUTIC AGENTS - An antibody of the invention interacts with human DR5 or with human DR4 to produce agonistic or antagonistic effects downstream of the receptor including inhibition of cell proliferation and apoptosis. Methods and uses for the antibodies, optionally in combination with various therapeutic agents, are detailed, including treatment of apoptosis-related disease and treatment of dysregulated cell growth. | 01-06-2011 |
| 20100331268 | Nitrated Lipids and Methods of Making and Using Thereof - Described herein are nitrated lipids and methods of making and using the nitrated lipids. | 12-30-2010 |
| 20100316631 | Water Soluble Curcumin-Based Compounds - The present disclosure describes the design and synthesis of a novel class of water soluble curcumin-based compounds. These water soluble curcumin-based compounds are shown to provide superior cell killing activity and exhibit increased and cell internalization solubility in aqueous solutions as compared to the free (unconjugated) curcumin. The present disclosure provides compositions for the treatment or prevention of a variety of disease states or conditions, such as but not limited to, cancer, other cell hyperproliferative disorders and chronic inflammatory conditions, said compositions comprising a water soluble curcumin-based compound. | 12-16-2010 |
| 20100305195 | MICRORNA MEDIATOR OF CARDIOMYOPATHY AND HEART FAILURE - Provided herein is a microRNA, specifically, β-myosin microRNA, compositions comprising β-myosin microRNA and methods of inhibiting or reducing expression of β-myosin microRNA. Also provided are genetically modified cells and animals comprising exogenous β-myosin microRNA. Provided herein are methods of screening for agents that modulate β-myosin microRNA expression. In addition, methods of identifying target genes that are regulated by β-myosin microRNA and methods of modulating such genes are described. Methods of diagnosing or determining whether a subject is at risk for a cardiovascular disorder are also described. | 12-02-2010 |
| 20100286212 | Treating and Preventing Viral Infections - Compounds that are useful in treating or preventing viral infections, such as influenza, are described herein. Further described are compositions made from these compounds and methods for using the compounds and their compositions in treating or preventing viral infections. | 11-11-2010 |
| 20100285007 | DIFFERENTIAL DIAGNOSIS OF B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA - Provided are methods of diagnosing in a subject a type of B-cell chronic lymphocytic leukemia (B-CLL). Also provided are antibodies, including monoclonal antibodies, that specifically bind FCRL2, FCRL3 or FCRL5 and methods of treating B-CLL using the antibodies. | 11-11-2010 |
| 20100284999 | CHARACTERIZATION OF THE CBIR1 ANTIGENIC RESPONSE FOR DIAGNOSIS AND TREATMENT OF CROHN'S DISEASE - This invention provides methods of diagnosing or predicting susceptibility to Crohn's Disease by determining the presence or absence of genetic variants. In one embodiment, the present invention provides methods to diagnose and/or predict susceptibility to Crohn's Disease in an individual by determining the presence or absence of anti-Cbir1 reactivity and the presence or absence of TLR5 risk variants. In another embodiment, the present invention provides methods to diagnose Crohn's Disease by determining the presence or absence of NFKB1 haplotype H3 and/or ASCA expression. In another embodiment, the present invention provides methods of diagnosing Crohn's Disease by determining the presence or absence of Cbir1 specific peripheral blood T cell proliferation. | 11-11-2010 |
| 20100246610 | Mid-IR Laser Instrument for Analyzing a Gaseous Sample and Method for Using the Same - An optical nose for detecting the presence of molecular contaminants in gaseous samples utilizes a tunable seed laser output in conjunction with a pulsed reference laser output to generate a mid-range IR laser output in the 2 to 20 micrometer range for use as a discriminating light source in a photo-acoustic gas analyzer. | 09-30-2010 |
| 20100239691 | MODULATING LATENCY AND REACTIVATION OF MYCOBACTERIUM TUBERCULOSIS - Methods for screening for agents that modulate the activation state, i.e., active growth or persistence, of | 09-23-2010 |
| 20100227341 | Diagnosing Pneumococcal Pneumonia - Compositions and methods for eliciting an immune response against | 09-09-2010 |
| 20100215576 | DIAGNOSIS AND TREATMENT OF NEUROECTODERMAL TUMORS - The present invention provides fusion proteins for the detection and treatment of neuroectodermal tumors. Previous work demonstrated that chlorotoxin is specific for glial-derived or meningioma-derived tumor cells. The current invention has extended the use of chlorotoxin-cytotoxin fusion proteins to treat the whole class neuroectodermal tumors such as gliomas, meningiomas, ependymonas, medulloblastomas, neuroblastomas, gangliomas, pheochromocytomas, melanomas, PPNET's, small cell carcinoma of the lung, Ewing's sarcoma, and metastatic tumors in the brain. Also, diagnostic methods are provided for screening neoplastic neuroectodermal tumors. | 08-26-2010 |
| 20100209457 | PNEUMOCOCCAL SEROTYPE 6D - Disclosed is a new and emerging serotype of | 08-19-2010 |
| 20100203009 | Pathway for Th-17 Cell Development and Methods Utilizing Same - The present disclosure demonstrates for the first time that Th-17 cells are the product of a distinct CD4 | 08-12-2010 |
| 20100173338 | Biomarkers for Cancer Sensitivity and Uses Thereof - Disclosed herein are biomarkers and uses thereof for evaluating anti-cancer efficacy and sensitivity. | 07-08-2010 |
| 20100168606 | Improved Photobleaching Method - The present disclosure provides an improved method for photobleaching an eye of a subject. The disclosed method may be used in a number of psychophysical test methods, including, but not limited to, measurement of dark adaptation. The improved method for photo-bleaching involves at least one of the following improvements: (i) the use of a bleaching light emitting a particular wavelength of light or a tailored spectrum of wavelengths; (ii) restricting or otherwise spatially tailoring the region of the retina that is subject to photobleaching; and (iii) utilizing a bleaching light having an intensity that is at or below the intensity of ambient daylight. The present disclosure additionally provides a combination of a photobleaching light and an apparatus to administer a psychophysical test suitable for use in practicing the disclosed methods. | 07-01-2010 |
| 20100167980 | Prolyl Endopeptidase Inhibitors For Reducing or Preventing Neutrophilic Inflammation - Provided herein are methods for reducing or preventing neutrophilic inflammation in a subject comprising selecting a subject with or at risk for neutrophilic inflammation and administering to the subject an agent that inhibits the expression or activity of prolyl endopeptidase. Provided herein are also methods for treatment or prevention of diseases associated with neutrophilic inflammation. | 07-01-2010 |
| 20100166654 | Single-Drug Multi-Ligand Conjugates for Targeted Drug Delivery - An adhesive is provided containing at least one synthetic polymer with receptor sites that enable the selective capture or release of a target molecule. A polymer is synthesized by polymerizing and cross-linking a functional monomer or functional copolymers in the presence of a target or template molecule allowing for reversible interactions between the polymer and the target molecule. The target molecule may be extracted from the polymer creating receptor sites complimentary to the target molecule. Alternatively, the target molecule may remain in the polymer network and be controllably released. The molecularly imprinted polymer is formulated into an adhesive. The adhesive can be used as a component in an in-vitro diagnostic device to release template molecules or to capture target molecules in vacated receptor sites in the synthetic polymer. | 07-01-2010 |
| 20100150889 | Polycistronic Vector For Human Induced Pluripotent Stem Cell Production - Methods of producing induced pluripotent stem (iPS) cells are provided. For example, a method of producing an iPS cell from a differentiated cell, which includes transforming the differentiated cell with a first vector comprising a nucleic acid sequence comprising a nucleic acid sequence encoding an Oct4, a nucleic acid sequence encoding a Sox2, and a nucleic acid sequence encoding a Klf4. Each of the nucleic acid sequences are separated from each other by a first and second viral 2A sequence. The method described can further comprise culturing the transformed cell under conditions that allow for the production of an iPS cell and isolating the cultured iPS cell. | 06-17-2010 |
| 20100144779 | Marine Alkalod Makaluvamines and Derivatives Thereof - The present disclosure provides compounds based on the marine alkaloid makaluvamine. Described are compounds of the general formula (I) and (II). Also described are pharmaceutical compositions comprising one or more of the compounds of the general formula (I) and (II). The compounds and pharmaceutical compositions described inhibit the growth of several cancer lines, induce apoptosis and cell cycle arrest, display topoisomerase II inhibitory activity and modulate the activity and/or expression of key proteins involved in the regulation of cell growth. Methods of treatment and prevention using the compounds and pharmaceutical compositions described are also provided. | 06-10-2010 |
| 20100143440 | UL97 INHIBITORS FOR TREATMENT OF PROLIFERATIVE DISORDERS - Methods and compositions related to treating or preventing a proliferative disease in a subject comprising administering an inhibitor of a UL97 or a UL97 homolog to the subject are described. | 06-10-2010 |
| 20100135951 | Agents and Methods Related to Reducing Resistance To Apoptosis-Inducing Death Receptor Agonists - Provided herein is a method of reversing or preventing a target cell's resistance to a death receptor agonist. Also provided are methods of screening for biomarkers resistance of and monitoring resistance to death receptor agonists. Also provided are methods of selectively inducing apoptosis in a target cell, treating a subject with cancer, autoimmune or inflammatory diseases, comprising administering compositions provided herein. Further provided are compositions comprising agents that modulate CARD containing proteins. | 06-03-2010 |
| 20100077647 | Aiming Systems - Provided herein are systems for aiming devices. For example, the aiming systems can be used to aim a firearm. The aiming systems can comprise a front sight portion having a cross-section with a truncated triangle shape when viewed by an operator aiming the device. The aiming systems can further comprise a rear sight portion including a notch having a truncated triangle shape with a base, a left side, a right side, and an opening that is narrower than the base. The front sight portion is alignable relative to the notch for aiming the device. | 04-01-2010 |
| 20100063137 | Cytotoxin Compound And Method of Isolation - The present invention concerns compounds derived from tunicates of the species | 03-11-2010 |
| 20090328241 | MITOCHONDRIAL-NUCLEAR EXCHANGED CELLS, TISSUES, ORGANS AND ANIMALS - Provided herein are mitochondrial-nuclear exchanged cells and animals comprising mitochondrial DNA (mtDNA) from one subject and nuclear DNA (nDNA) from a different subject. Methods for producing a mitochondrial-nuclear exchanged animal and animals made by the methods are provided. Also provided are methods of screening for agents useful for treating a disease or disorder using mitochondrial-nuclear exchanged animals or cells, tissues or organs thereof. | 12-31-2009 |
| 20090208483 | ANTIBODY SELECTIVE FOR DR4 AND USES THEREOF - An antibody of the invention interacts with human DR5 or with human DR4 to produce agonistic or antagonistic effects downstream of the receptor including inhibition of cell proliferation and apoptosis. Nucleic acid sequences and amino acid sequences of DR5 and DR4 antibodies have been elucidated and vectors and cells containing and expressing these sequences have been generated. Methods and uses for the antibodies are detailed including treatment of apoptosis-related disease and treatment of dysregulated cell growth. | 08-20-2009 |
| 20090191185 | Reducing Cancer Cell Invasion Using an Inhibitor of Toll Like Receptor Signaling - Provided herein are methods and compositions for reducing the invasiveness of cancer cells. Such methods and compositions are particularly useful for cancer cells that express a member of the Toll Like Receptor9 (TLR9) subfamily and are useful in selecting the proper treatment for a subject with cancer. | 07-30-2009 |
| 20090075941 | TREATING NEOPLASMS - Methods of treating a subject with neoplasm (e.g., mesothelioma) or at risk of developing neoplasm by administering a mevalonate pathway inhibitor such as a nitrogen-containing bisphosphonate are disclosed. Examples of nitrogen-containing bisphosphonates include alendronate, ibandronate, minodronate, neridronate, olpadronate, pamidronate, risedronate, and zoledronate. The methods can further include the administration of a p38 inhibitor. Further disclosed are compositions and kits including a nitrogen-containing bisphosphonate and optionally a p38 inhibitor. | 03-19-2009 |
| 20090068197 | MYCOBACTERIAL DISEASE DETECTION, TREATMENT, AND DRUG DISCOVERY - Methods for detecting and treating | 03-12-2009 |
| 20090022707 | Combinations of Antibodies Selective for a Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor and Other Therapeutic Agents - An antibody of the invention interacts with human DR5 or with human DR4 to produce agonistic or antagonistic effects downstream of the receptor including inhibition of cell proliferation and apoptosis. Methods and uses for the antibodies, optionally in combination with various therapeutic agents, are detailed, including treatment of apoptosis-related disease and treatment of dysregulated cell growth. | 01-22-2009 |
| 20080318884 | Methods for Altering Gene Expression and Methods of Treatment Utilizing Same - The present disclosure describes methods for altering the expression of a target gene comprising a rare cluster of codons, including, but not limited to, trinucleotide repeats. The method utilizes, in part, on amino acid deprivation or the limiting of specific charged tRNAs. The methods for altering target gene expression may be used in treatment methods to treat diseases in a subject organism in need of such treatment. Such methods for altering target gene expression have not been heretofore recognized in the art. Exemplary diseases that may be treated using the methods of the present disclosure include any disease where altering the expression of the target gene would provide treatment. Such diseases include all forms of cancer, ageing, infectious disease, metabolic disorders, inflammation, neurological disorders, diabetes, psychiatric disorders and diseases associated with trinucleotide repeats. | 12-25-2008 |
| 20080206199 | Chimeric Herpes Viruses and Uses Thereof - Disclosed herein are chimeric herpesviruses as well as methods of making and using such chimeric herpesviruses. The chimeric viruses comprise two nucleic acid sequences, one from a herpesvirus and one from a different virus. The herpesvirus nucleic acid sequence is a modified protein kinase R (PKR) evasion gene. The second viral nucleic acid sequence inhibits PKR-mediate protein shutoff in tumor cells, but is not neurovirulent. Thus, the chimeric virus has reduced neurovirulence as compared to the wild-type herpesvirus but remains replication competent. | 08-28-2008 |
